In contrast, for patients without viral infection, with ECOG PS = 0, without EHS, and with AFP ≥400 ng/mL, dual ICI therapy was more beneficial, particularly in patients with AFP ≥400 ng/mL (HR = 0.66, 95% CI 0.52-0.83) (Table 3). The gene discussed is AFP; the disease is viral infectious disease.